"What's needed are vaccines that are durable, with a wide breadth of protection."
Machine-learning models created by a National Institutes of Health (NIH)-supported research team can identify, with high accuracy, patients likely to have long COVID, according to a study yesterday in The Lancet Digital Health.
Michigan's Department of Natural Resources (DNR) yesterday reported three highly pathogenic avian flu cases in red fox kits in three different counties, which came closely on the heels of a similar report from Minnesota.
An analysis of antibiotic use for upper respiratory infections (URIs) in Ghana reveals the considerable economic impact of inappropriate prescribing can have on low-resource settings, researchers reported last week in Antimicrobial Resistance & Infection Control.
A Centers for Disease Control and Prevention (CDC) modeling study used data from 59 US case investigation and contact tracing (CICT) programs to estimate that the programs prevented 1.11 to 1.36 million COVID-19 cases, and 27,000 to 34,000 hospitalizations over 60 days in winter 2020-21, well before the Delta and Omicron variant surges.
Late last week the US Centers for Disease Control and Prevention (CDC) posted an outbreak notice about an Escherichia coli O157:H7 outbreak related to mixed leafy greens.
UK researchers estimate that an additional 2, 1, and 6 cases of myocarditis occur per 1 million people in the week after one dose of the AstraZeneca/Oxford, Pfizer/BioNTech, and Moderna COVID-19 vaccines, respectively, while a positive SARS-CoV-2 test was tied to much higher odds of that and other serious heart conditions.
The World Health Organization (WHO) today recommended the RTS,S malaria vaccine for children in sub-Saharan Africa and other areas of moderate and high Plasmodium falciparum malaria transmission. The recommendation paves the way for global health groups to make funding and vaccine rollout plans and for countries to decide whether to include vaccination in their malaria control programs.
High-risk adults with mild to moderate COVID-19 who receive a dose of casirivimab and imdevimab have lower hospitalization rates than those who don't, according to a randomized, controlled trial today in The Lancet's EClinicalMedicine. The casirivimab and imdevimab combination is under emergency use authorization by the US Food and Drug Administration.
Discontinuing antibiotics for uncomplicated respiratory tract infections (RTIs) when a physician has determined that antibiotics aren't needed is a safe strategy for reducing unnecessary antibiotic use, according to the results of a randomized clinical trial published yesterday in Clinical Microbiology and Infection.